The Wegovy pill in the UK: separating fact from the noise

The biggest myth: 'it's basically just the injection in a tablet'

People assume the Wegovy tablet is a convenient swap for the weekly injection, same drug, same effect, just easier to take. That is partly true and partly misleading. Both contain semaglutide and activate the GLP-1 receptor, reducing appetite and slowing gastric emptying. The licensed maintenance dose for the injection is 2.4 mg weekly; for the tablet it is 25 mg daily. The higher tablet dose compensates for the far lower oral bioavailability of semaglutide, only a small fraction of each tablet reaches the bloodstream, which is why the SNAC absorption enhancer is co-formulated with it.

What this means in practice is that the tablet comes with rules the injection does not. It must be taken first thing in the morning on an empty stomach with a small amount of plain water (up to about 120 ml). Nothing else (no coffee, no food, no other oral medicines) for at least 30 minutes afterwards. Miss that window and you significantly reduce how much semaglutide your body absorbs. For people whose mornings are reliably uninterrupted, this is manageable. For shift workers or anyone who wakes and immediately eats, it takes more planning than the injection ever did. The practical side of taking Wegovy tablets is worth thinking through before you decide.

The upside the injection cannot match: no needles, no refrigeration. The tablets are stored at room temperature, which makes travel and everyday life simpler for many people. That is a real, meaningful difference for a significant proportion of patients.

What the trial results actually showed, and the framing that matters

The OASIS 4 phase 3 trial enrolled 307 adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, over 64 weeks alongside lifestyle changes. The headline figure from the MHRA's approval communications is an average weight loss of around 13.6% compared with around 2.4% on placebo. Among participants who adhered fully to the protocol the figure was closer to 16–17%. That distinction matters: the higher number is real but conditional. When you see it quoted (including on some treatment pages) it should always carry the caveat that it reflects full adherence, not the overall trial average.

For context, the weekly Wegovy injection at 2.4 mg produced around 15% average weight loss in the STEP 1 trial over 68 weeks, as reported in the New England Journal of Medicine. The oral tablet's average result is modestly lower, though head-to-head data are limited. Whether the convenience of a daily tablet outweighs a possible difference in average outcome is a personal and clinical question. Our clinical team reviews each case individually, there is no single right answer across the board.

Most common side effects in the trial were gastrointestinal: nausea, vomiting, diarrhoea and constipation, reported by around 74% of the oral semaglutide group versus 42% on placebo. These were generally mild to moderate and tended to ease as the body adjusted, particularly after each dose step.

Who the Wegovy pill is licensed for in the UK

The MHRA has licensed the Wegovy tablet for adults with a BMI of 30 or above, or a BMI of 27–29.9 alongside at least one weight-related condition such as high blood pressure, high cholesterol, obstructive sleep apnoea or prediabetes. If you are weighing up whether the Wegovy pill could be suitable for your situation, understanding the licensed criteria is a useful starting point. It is taken alongside a reduced-calorie diet and increased physical activity, the tablet supports those changes, it does not replace them.

It is not licensed for use in pregnancy, and women who are breastfeeding or actively trying to conceive should not use it. It is not authorised for under-18s. People with a history of certain gastrointestinal conditions or pancreatitis will need careful prescriber assessment before starting any GLP-1 medicine. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance, this is something the prescriber factors in during the consultation.

The Wegovy tablet is not yet available on the NHS; it would require a NICE appraisal before that route opens. For now it is available through private prescription only. If you want to understand what private oral semaglutide costs and what an honest price should include, that page lays it out plainly. One thing worth knowing: a legitimate private price covers the consultation, the prescription and aftercare, not just the tablets themselves.

It is also worth being clear about what the Wegovy tablet is not. Rybelsus is also an oral semaglutide tablet, but it is licensed for type 2 diabetes at doses of 3 mg, 7 mg and 14 mg. Those are not steps on the weight-loss tablet ladder. If you have seen those strengths discussed in a weight-loss context, that is a category error, and reading about the Wegovy pill form specifically helps clarify why this product is distinct from other oral semaglutide options. The full picture on semaglutide tablets covers both products and why the distinction matters.

Getting started through a regulated UK pharmacy

Because these are prescription-only medicines, the legal route in the UK runs through a clinical assessment, there is no shortcut. At nume, a GPhC-registered Independent Prescriber reads your consultation on the same day it is submitted. Not software, not an automated triage tool: a real clinician who checks your health history, your current medicines and whether oral semaglutide is the right fit. Identity is verified and weight confirmed before any prescription is issued.

If approved, your order is dispatched the same day for free next-working-day delivery via DPD. The box arrives plain and unbranded, nothing on the outside to indicate what is inside. Our pharmacy's GPhC registration (number 9012878) is publicly verifiable at the GPhC pharmacy register, which is the first thing any reputable online pharmacy should be able to point you to.

If you want to explore whether the Wegovy tablet or another licensed treatment suits your situation, the free consultation is the place to start. There is no obligation, and the prescriber review is thorough. Worth checking.